RAPT Therapeutics (RAPT) Stock Forecast & Price Target

Compare

432 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RAPT Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

RAPT

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RAPT Stock 12 Month Forecast

Average Price Target

$64.38

▲(76.53% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for RAPT Therapeutics in the last 3 months. The average price target is $64.38 with a high forecast of $72.00 and a low forecast of $56.00. The average price target represents a 76.53% change from the last price of $36.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","73":"$73","22.75":"$22.8","39.5":"$39.5","56.25":"$56.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,22.75,39.5,56.25,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,34.62461538461539,37.73923076923077,40.853846153846156,43.96846153846154,47.08307692307692,50.19769230769231,53.31230769230769,56.426923076923075,59.54153846153846,62.65615384615384,65.77076923076923,68.88538461538461,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,34.03846153846154,36.566923076923075,39.09538461538462,41.62384615384615,44.15230769230769,46.68076923076923,49.209230769230764,51.7376923076923,54.26615384615384,56.79461538461538,59.32307692307691,61.85153846153845,{"y":64.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,33.393846153846155,35.277692307692305,37.16153846153846,39.04538461538462,40.92923076923077,42.81307692307692,44.69692307692308,46.580769230769235,48.464615384615385,50.348461538461535,52.23230769230769,54.11615384615385,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.87,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$72.00

Average Price Target$64.38

Lowest Price Target$56.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

Buy

―

Initiated

12/18/25

TD Cowen Initiates a Buy Rating on RAPT Therapeutics (RAPT)

Emily Bodnar

H.C. Wainwright

$72

Buy

97.42%

Upside

Reiterated

12/05/25

RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart

Anupam Rama

J.P. Morgan

$55→$57

Buy

56.29%

Upside

Reiterated

11/11/25

J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)

Etzer Darout

Barclays

$58→$56

Buy

53.55%

Upside

Reiterated

11/07/25

Barclays Remains a Buy on RAPT Therapeutics (RAPT)

Sam Slutsky

LifeSci Capital

$72→$68

Buy

86.45%

Upside

Reiterated

11/06/25

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

Kaveri Pohlman

Clear Street

$60

Buy

64.52%

Upside

Reiterated

11/06/25

Rapt Therapeutics shares 'exceptionally compelling,' says Clear StreetRapt Therapeutics shares 'exceptionally compelling,' says Clear Street

Yanan Zhu

Wells Fargo

$48→$72

Buy

97.42%

Upside

Reiterated

11/03/25

Rapt Therapeutics price target raised to $72 from $48 at Wells FargoRapt Therapeutics price target raised to $72 from $48 at Wells Fargo

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$70

Buy

91.94%

Upside

Initiated

10/27/25

RAPT Therapeutics (RAPT) Receives a Buy from Guggenheim

Thomas Smith

Leerink Partners

$37→$60

Buy

64.52%

Upside

Reiterated

10/21/25

Leerink Partners Keeps Their Buy Rating on RAPT Therapeutics (RAPT)

Eliana Merle

UBS

$8→$9

Hold

-75.32%

Downside

Reiterated

08/12/25

Rapt Therapeutics price target raised to $9 from $8 at UBSRapt Therapeutics price target raised to $9 from $8 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

Buy

―

Initiated

12/18/25

TD Cowen Initiates a Buy Rating on RAPT Therapeutics (RAPT)

Emily Bodnar

H.C. Wainwright

$72

Buy

97.42%

Upside

Reiterated

12/05/25

RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart

Anupam Rama

J.P. Morgan

$55→$57

Buy

56.29%

Upside

Reiterated

11/11/25

J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)

Etzer Darout

Barclays

$58→$56

Buy

53.55%

Upside

Reiterated

11/07/25

Barclays Remains a Buy on RAPT Therapeutics (RAPT)

Sam Slutsky

LifeSci Capital

$72→$68

Buy

86.45%

Upside

Reiterated

11/06/25

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

Kaveri Pohlman

Clear Street

$60

Buy

64.52%

Upside

Reiterated

11/06/25

Rapt Therapeutics shares 'exceptionally compelling,' says Clear StreetRapt Therapeutics shares 'exceptionally compelling,' says Clear Street

Yanan Zhu

Wells Fargo

$48→$72

Buy

97.42%

Upside

Reiterated

11/03/25

Rapt Therapeutics price target raised to $72 from $48 at Wells FargoRapt Therapeutics price target raised to $72 from $48 at Wells Fargo

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$70

Buy

91.94%

Upside

Initiated

10/27/25

RAPT Therapeutics (RAPT) Receives a Buy from Guggenheim

Thomas Smith

Leerink Partners

$37→$60

Buy

64.52%

Upside

Reiterated

10/21/25

Leerink Partners Keeps Their Buy Rating on RAPT Therapeutics (RAPT)

Eliana Merle

UBS

$8→$9

Hold

-75.32%

Downside

Reiterated

08/12/25

Rapt Therapeutics price target raised to $9 from $8 at UBSRapt Therapeutics price target raised to $9 from $8 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RAPT Therapeutics

1 Month

xxx

Success Rate

6/7 ratings generated profit

Average Return

+19.74%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +19.74% per trade.

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+81.16%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +81.16% per trade.

1 Year

Emily BodnarH.C. Wainwright

Success Rate

6/7 ratings generated profit

Average Return

+147.01%

reiterated a buy rating 19 days ago

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +147.01% per trade.

2 Years

xxx

Success Rate

6/7 ratings generated profit

Average Return

+147.01%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +147.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RAPT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RAPT has received 19 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RAPT average Analyst price target in the past 3 months is 64.38.

Each month's total comprises the sum of three months' worth of ratings.

RAPT Financial Forecast

RAPT Earnings Forecast

Next quarter’s earnings estimate for RAPT is -$0.81 with a range of -$1.30 to -$0.57. The previous quarter’s EPS was -$0.65. RAPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RAPT has Performed in-line its overall industry.

RAPT Sales Forecast

Next quarter’s sales forecast for RAPT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RAPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RAPT has Performed in-line its overall industry.

RAPT Stock Forecast FAQ

What is RAPT’s average 12-month price target, according to analysts?

Based on analyst ratings, RAPT Therapeutics’s 12-month average price target is 64.38.

What is RAPT’s upside potential, based on the analysts’ average price target?

RAPT Therapeutics has 76.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RAPT a Buy, Sell or Hold?

RAPT Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is RAPT Therapeutics’s price target?

The average price target for RAPT Therapeutics is 64.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $72.00 ,the lowest forecast is $56.00. The average price target represents 76.53% Increase from the current price of $36.47.

What do analysts say about RAPT Therapeutics?

RAPT Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RAPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

RAPT Therapeutics (RAPT) Stock Forecast & Price Target

RAPT Analyst Ratings

RAPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RAPT Therapeutics

RAPT Analyst Recommendation Trends

RAPT Financial Forecast

RAPT Earnings Forecast

RAPT Sales Forecast

RAPT Stock Forecast FAQ

Detailed List of Analyst Forecasts